ÂÜÀòÂÒÂ×

Dr Cathy Eng is a professor of Gastrointestinal Medical Oncology at Vanderbilt-Ingram Cancer Center (VICC), acting as co-leader of the VICC Gastrointestinal Cancer Research Program. She also oversees a large expansion in the clinical and research activities of the medical oncology gastrointestinal cancer disease group at Vanderbilt, as well as developing programs for adolescent and young adult (AYA) oncology services.

Previously, she has been with MD Anderson for 17 years, where she has served as the associate director of the Colorectal Center, chair of the Clinical Research Committee and chair of the Multidisciplinary Colorectal Cancer Tumor Board.

She holds numerous leadership roles in the field of gastrointestinal cancer. Dr Eng is serving her second term as National Cancer Institute (NCI) Rectal/Anal Cancer Task Force chair. She is the lead contact principal investigator for the NCI National Clinical Trials Network (NCTN) Leading Academic Participating Sites grant for two terms. She was recently elected co-chair of the Rectal/Anal Subcommittee for the Southwest Oncology Group (SWOG) and serves on the ECOG-ACRIN Cancer Research Group gastrointestinal committee. She has served as a volunteer and as a leader in numerous roles in the American Society of Clinical Oncology (ASCO) since 2002 and was acknowledged at the ASCO 2019 Annual Meeting for her years of volunteer service, dedication and commitment to ASCO with a Fellow of the American Society of Clinical Oncology (FASCO) distinction.

Dr Eng has been a principal investigator of innumerable national and international trials, including investigator-initiated trials, NCI-funded trials and major pharmaceutical-sponsored trials. Her work has led to numerous practice-changing outcomes, particularly with regard to the use of immunotherapy in metastatic anal cancer. Particularly due to her groundbreaking work in anal cancer, she served as the section leader for the Rare Cancers Subsection for the MD Anderson HPV Malignancies Moonshot Program.